Introduction: Rheumatoid arthritis (RA) is an autoimmune disease resulting in chronic inflammation of the joints and extra-articular tissues characterized by persistent inflammatory synovitis, usually involving the peripheral joints in a symmetric manner. The disease Amavata described in Ayurveda has similar symptomatology to that of RA.
INTRODUCTION
Rheumatoid arthritis is a chronic multisystem disease, which affects joints and extra-articular tissues characterized by persistent inflammatory synovitis, usually involving the peripheral joints in a symmetric manner. 1 Rheumatoid arthritis has a worldwide prevalence of 0.5 to 1% in the adult population. The onset is most frequent during the fourth and fifth decades of life. The exact etiopathogenesis of the disease is still the subject of contention, but most theories advocate RA as an autoimmune-mediated condition. 2 Condition with similar picture has been described under the heading "Amavata" in Ayurveda. According to Ayurveda, the main cause of the disease Amavata is irregular dietary habits and sedentary lifestyle. An irregular dietary habit causes jatharagnimandya (diminution of digestive fire), which leads to "Ama" (unmetabolized or semidigested food) formation. Because of sedentary activities and irregular dietary habits "Vata" vitiates, carries the Ama to various Kapha sthanas (loci of kapha dosha) like Sandhi (joints), Urah (thorax), Sirah (head), Kantha (throat), and causes the disease Amavata. 3 The exact etiology and pathogenesis of RA remain unclear. Rheumatoid arthritis requires an integrated approach that includes use of nonpharmacologic therapies and pharmacologic agents, such as nonbiologic and biologic disease-modifying antirheumatic drugs, nonsteroidal anti-inflammatory drugs, analgesics, and corticosteroids. These medicines do provide symptomatic relief and slow down the progression of the disease/ development of the deformities in certain patients but have limitations owing to their adverse effects. Ayurvedic formulations have been in use since ages and have found to be useful in treating RA and also in improving the prognosis. Vatari Guggulu and Rasnasaptaka kashaya are formulations that are commonly used in joint diseases in Ayurveda. Brihat Saindhavadya taila is prescribed for external application in inflamed joints to reduce the symptoms of Ama in Sandhi (joints). This study was conducted to comparatively assay the clinical efficacy and safety of internal administration of Vatari Guggulu and Rasnasaptaka kashaya (Shunthi churna prakshepa) in one group and a combination of internal administration of the same together with external application of Brihat Saindhavadya taila in second group was taken up for clinical evaluation.
OBJECTIVES
To assess the clinical efficacy and safety of Vatari Guggulu, Rasnasaptaka kashaya, and Brihat Saindhavadya taila in the management of RA.
MATERIALS AND METHODS

Study Design
The study was randomized conducted as a multicenter open-labeled, prospective study executed at OPD level at four institutes centers of CCRAS, under Ministry of AYUSH. The study was approved by the Institutional Ethical Committee of all the four participating centers and was conducted according to the Declaration of Helsinki for clinical trials and existing guidelines of good clinical practice of the country and registered in the Clinical Trial Registry of India vide CTRI Reg (CTRI//2014/05/004629).
Study Participants
A total of 230 participants were enrolled in the trial from four peripheral institutes of CCRAS, viz., Regional Ayurveda Research Institute for Skin Disorders, Vijayawada; Central Ayurveda Research Institute for Cardiovascular Diseases, New Delhi; Regional Ayurveda Research Institute for Endocrine Diseases, Jaipur; and Achanta Lakshmipathi Research Center for Ayurveda, Chennai. Patients were screened in accordance with the inclusion and exclusion criteria and were recruited in the study after obtaining the written informed consent. The cases were randomly allocated to two groups and out of 230 cases, 201 cases completed the study and 29 cases dropped out in the course of study.
Inclusion Criteria
Patients of either sex with age between 20 and 60 years, willing to participate in the study for 12 weeks and presence of any four out of the seven criteria (American College of Rheumatology, 1987), 4 viz., morning stiffness: Stiffness in and around joints lasting 1 hour before maximal improvement, arthritis of three or more joints, at least three joint areas, observed by physician, having pain with soft tissue swelling or joint effusion, not just bony overgrowth, arthritis of hand joints, at least one area in wrist and hand is swollen, symmetric arthritis, presence of rheumatoid nodules, serum rheumatoid factor positive, typical radiographic changes of arthritis on posteroanterior view of hand and wrist radiograph that must include erosions or unequivocal bony decalcification, and localized in or adjacent to involved joints.
Exclusion Criteria
Patients who have developed complications of RA, e.g., deformity of joints/bones, pleura-pericardial disease, patients who are unable to walk without support and/or confined to wheelchair, those with structural deformity as the complication of RA, poorly controlled hypertension (≥160/100 mm Hg), patients suffering from diabetes mellitus [(F) > 126 mg/dL], other types of arthritis like gouty arthritis, tuberculous arthritis, patients on prolonged (>6 weeks) medication with corticosteroids, antidepressants, anticholinergics or any other drugs that may have an influence on the outcome of the study, past history of atrial fibrillation, acute coronary syndrome, myocardial infarction, stroke or severe arrhythmia in the last 6 months, symptomatic patients with clinical evidence of heart failure, concurrent serious hepatic disorder (defined as aspartate aminotransferase and/ or alanine aminotransferase, total bilirubin, alkaline phosphatase > two times upper normal limit) or renal disorders (defined as serum creatinine >1.2 mg/dL), severe pulmonary dysfunction (uncontrolled bronchial asthma and/or chronic obstructive pulmonary disease), or any other condition that may jeopardize the study, alcoholics and/or drug abusers, h/o hypersensitivity to any of the trial drugs or their ingredients, pregnant/lactating woman, and patients who have completed participation in any other clinical trial during the past 6 months were exempted from the study.
Laboratory Investigations
The laboratory investigations hemoglobin, total leukocyte count, differential leukocyte count, ESR, blood sugar, blood urea, serum uric acid, serum creatinine, liver function test (LFT), CRP, antistreptolysin O titer, RA factor (immunoturbidity test), X-ray of hand and wrist, and electrocardiography were carried out.
Outcomes
Primary Outcome Measure
• Changes in DAS-28 score 5 
Secondary Outcome Measures
• Change in Disability index (the Indian Health Assessment Questionnaire) 6 • Change in Acute phase reactants-ESR and CRP • Change in Health Questionnaire SF-36 7
Study Interventions
The formulations fulfilling the physicochemical standards and quality parameters and prepared as per standard operating procedures were procured from Good Manufacturing Practice-certified companies. Patients in group I were administered Vatari Guggulu 8 1.5 gm (3 tablets of 500 mg each) twice daily after food with lukewarm water and Rasnasaptaka kashaya 9 15 mL with prakshep of 1 gm Shunthi churna 10 twice daily before food internally and in group II Brihat Saindhavadya taila 11 20 mL was used for external application twice daily over affected joints along with internal administration of Vatari Guggulu and Rasnasaptaka kashaya with the same dosage mentioned as for group I. The duration of treatment was for 12 weeks. The drug compliance was assessed on each visit during the study.
Study Procedure
On the enrollment day at baseline (visit 1), patient's demographic profile, medical history, family history, Sharirik Prakriti, and vital parameters were recorded. General physical and systemic examination, assessment of DAS-28 scale, assessment of disability index, SF-36 scoring, and assessment of ayurvedic parameters were done at baseline and on 84th day. Subsequent visits were planned at an interval of 14 days [14th day (visit 2), 28th day (visit 3), 42nd day (visit 4), 56th day (visit 5), 70th day (visit 6), and 84th day (visit 7)]. Patients were assessed and given study medications at each subsequent visit till 84th day. There was also without medication follow-up after 15 days of the 90th day visit. Details of clinical assessment and study schedule are given in Flow Chart 1.
At the study site, data of all the patients were recorded in predesigned case report forms (CRFs) and were also entered in electronic formats (e-formats) designed in MS Excel with many data validation checks to ensure correct data entry. The e-formats and Xerox of the CRFs along with the laboratory investigations reports of the patients were sent by the participating centers to the council's headquarters on weekly basis for the purpose of clinical trial monitoring. A total of 230 participants were enrolled and were randomly allocated to two groups and out of 230 cases, 201 cases completed the study and 29 cases dropped out in the course of study. Last-observationcarried-forward (LOCF) was applied and a total of 225 (group I: 113 and group II: 112) cases were selected for statistical analysis. Flow Chart 2 shows the outflow of the patients in the study.
OBSERVATIONS AND RESULTS
Demographic Profile
Majority of the patients were female (80.9%); 34.2% cases were in the age group of 31 to 40 years followed by 32.4% in the age group of 41 to 50 years. Maximum patients were married (87.5%) and 84.4% patients were literate (read and write) and 64.8% patients were doing only household work. About 70.6% patients were from above poverty line and 71.1% patients were from urban area. Majority of patients were followers of Hinduism (91.1%) and about 53.3% patients were nonvegetarian. Most of the patients (91.5%) were not having any type of addiction. About 60.4% patients were having regular bowel habit while remaining 39.6% were having irregular bowel habit. Maximum (99%) of the patients were having emotional stress, out of which 45.3% patients were having moderate Flow Chart 1: Study schedule Flow Chart 2: Outflow of the patients in the study emotional stress while 18.66% patients having too much emotional stress. Most of the patients were of either Vatapittaja (31.11%) or Vata-kaphaja (31.11%) Prakriti followed by Pitta-kaphaja prakriti (30.66%). Demographic profile of the patients is given in Table 1 .
Effect of Medication
In group I, after 12 weeks of intervention, the mean DAS-28 score (primary outcome) reduced from 6.68 at baseline to 4.98 on 84th day showing statistically significant improvement (p < 0.001) (Graph 1). In Disability index the mean score at baseline was 1.53 and got reduced to 0.89 on 84th day showing statistically significant improvement (p < 0.001) (Graph 2). The acute phase reactants, ESR and CRP, did not undergo any statistically significant change. In SF-36 questionnaire, statistically significant improvement was observed in all the domains; physical functioning, role limitation due to physical health, limitations due to emotional problems, energy/fatigue, emotional well being, social functioning, pain and general health with p-value (p < 0.001), which is evident from Table 2 and Graph 3. Out of 72 RA factor-positive cases at baseline, total three cases converted to RA negative after 12 weeks of treatment (Tables 3 to 5 ). Chief complaint noticed was swelling in joints, which was present in 113 (100%) cases at baseline and after treatment, i.e., 84th day, it was present in 104 (92%) cases, morning stiffness was present in 112 (99.1%) cases at baseline, and after treatment, i.e., 84th day, it was present in 55 (48.7%) cases. Tenderness in joint was present in 109 (96.5%) cases at baseline and after treatment it was present in 102 (90.3%) cases. Fever was present in 66 (58.4%) cases at baseline and only in 5 (4.4%) cases at the end of trial period. Malaise/fatigue/ weakness was present in 108 (95.6%) cases at baseline and significantly improved at the end of trial period, in 42 (37.2%) cases (Table 6 ).
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In group II, after 12 weeks of trial period the mean DAS-28 score reduced from 6.62 at baseline to 4.89 on 84th day showing statistically significant improvement with (p < 0.001) (Graph 1). In disability index, the mean score at baseline was 1.59 and was reduced to 0.82 on 84th day showing statistically significant improvement (p < 0.001) (Graph 2). The acute phase reactants, ESR and CRP, did not undergo any statistically significant change. In SF-36 Questionnaire, statistically significant improvement was observed in all the domains; physical functioning, role limitation due to physical health, limitations due to emotional problems, energy/fatigue, emotional well being, social functioning, pain and general health with p-value (p < 0.001), which is evident from Table 2 and Graph 3. Out of 69 RA factor-positive cases at baseline, total 10 cases converted to RA negative after 12 weeks of treatment (Table 3) . About objective parameters based on chief complaints, swelling in joints was present in 112 (100%) cases at baseline and after treatment, i.e., 84th day, it was present in 93 (83%) cases, morning stiffness was present in 109 (97.3%) cases at baseline and after treatment, and at the end of 84th day it was present in 60 (53.6%) cases, tenderness in joint was present in 108 (96.4%) cases at baseline and after treatment, it was present in 94 (83.9%) cases, fever was present in 66 (58.9%) cases at baseline and after treatment, it was present in 2 (1.8%) cases. Malaise/ fatigue/weakness was present in 105 (93.8%) cases at baseline and after treatment, i.e., 84th day, it was present in 53 (47.3%) cases (Table 6) . 
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Safety Profile
The effect of this treatment on various safety parameters, such as LFTs and kidney function tests (KFTs) were assessed on baseline and at 84th day visit. No statistically significant change was observed in the LFT and renal function test (RFT) parameters at the end of the trial period (Table 7 , Graphs 4 and 5). In both the groups no adverse drug reaction or adverse events were reported during the study period. 
DISCUSSION
Rheumatoid arthritis is a chronic, progressive, inflammatory autoimmune disease associated with articular, extra-articular, and systemic effects. The exact etiopathogenesis is unclear but can be said to have multifactorial etiology ranging from infections to chromosomal factors. Ayurveda has described Amavata disease with similar symptomatology and describes the condition as a disease that occurs due to accumulation of ama (unmetabolized nonhomogeneous substance) in the joints. As per Ayurveda, provoked Vata dosha and Ama are the responsible factors for causation of the disease. Here, the treatment is aimed at bringing Vata dosha to normalcy and improving the jatharagni (digestive fire) so that to remove Ama. Drugs that possess katu (pungent taste), tikta rasa (bitter taste), and deepana (enhances digestive activity) qualities are useful for Amapachana (eliminating ama) and to increase Agnibala (metabolic power).
Rheumatoid arthritis is more prevalent in the middle aged and women and the results of the study are consistent with the fact. In this study, it has been observed that the maximum number of patients suffering from RA had emotional stress, which indicates that emotional stress may have a role in etiology of disease or may be an effect of the disease itself. Angamarda (body pain), Aruchi (anorexia), Trishna (excessive thirst), Alasaya (lethargy), Gaurava (heaviness in the body), Apaka (indigestion), Jwara (fever), Anga shunata (swelling in the body), Utsahahani (loss of interest in activities), Bahumutrata (polyuria), and Vairasya (distaste) described under the general features of Amavata in Ayurveda were reported by good number of patients in this study. Quite a good number of patients (60.44%) were having Nidraviparyaya (disturbed sleep pattern), which has been described as important complication of Amavata in Ayurveda.
This study revealed that the study formulations have potential role in the management of clinical features of RA. Statistical analysis report shows that there is significant improvement in primary outcome (DAS-28 score) and secondary outcome (disability index and Health Survey Questionnaire SF-36 in all the eight domains) after 12 weeks of treatment. Subjective improvement was also observed in various symptoms like morning stiffness, fever, fatigue, Aruchi (tastelessness), Trishna (thirst), Alasya (laziness), Gaurava (heaviness of body), Apaka (indigestion), Bahumutrata (polyuria), Praseka (salivation), Utsahhani (loss of enthusiasm), vairasya (distaste), jadyata (stiffness), and Nidraviparyaya (disturbed sleep pattern).
Above effects may be due to the Guggulu component of the formulation Vatari Guggulu. Guggulu contains guggulsterones, which reduce the level of proinflammatory cytokines cyclooxygenase-2 messenger ribonucleic acid level and suppress its tumor necrosis factor-α-mediated induction and activation. Its antirheumatic and analgesic properties have been reported. 12 14 Eranda (Ricinus communis) has been described as best medicine for Amavata in Ayurvedic classics and its anti-inflammatory and analgesic activity has been reported in experimental study. 15 Punarnava (Boerhaavia diffusa Linn.) has been described as best Shothahar drug in Ayurveda and its anti-inflammatory activities have been reported from experimental study. 16 More improvement in pain and tenderness was noticed in group II patients where Brihat Saindhavadya taila was given for local use along with other two trial medicines. Brihat Saindhavadya taila contains Saindhava lavana, Gaja pippali, Rasna, Satapushpa, Yavani, Sarjikshara, Shunthi, Yastimadhu, Ajamoda, Jeeraka, and Eranda taila. The Lavana (salts) has penetrating character and owing to it, it may help in eliminating the Ama accumulated in the joints. Majority of the drugs have Vatashamaka property, which might be responsible for analgesic effect and anti-inflammatory effect. The synergistic and cumulative effect of these formulations might be responsible for improving the subjective and objective parameters and primary and secondary outcomes of Amavata (RA).
CONCLUSION
Based on this open-label, prospective multicenter clinical study, it can be inferred that the combination of Ayurvedic formulations Vatari Guggulu, Rasnasaptaka kashaya with Shunthi churna prakshepa internally in group I and Vatari Guggulu, Rasnasaptaka kashaya with Shunthi churna prakshepa internally along with Brihat Saindhavadya taila externally in group II patients has good efficacy and safety profile in the management of Amavata (RA). Significant improvement in the clinical parameters and other assessment parameters, i.e., DAS-28 score, disability index (the Indian Health Assessment Questionnaire), Health Questionnaire SF-36 and slight change in acute phase reactants ESR and CRP, was observed in both the groups. However, more improvement in pain and tenderness of joints was observed in group II patients. No adverse drug reactions/adverse events have been reported in both the groups during study period. These drugs can be safely used for the management of RA. 
JRAS
